Search clinical trials for: ipratropium bromide

Total 944 results

Boehringer Ingelheim

Completed

Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
State University of New York at Buffalo
National Center for Advancing Translational Sciences (NCATS)

Completed

Defining and Treating Depression-related Asthma

Depression | Asthma | Childhood Asthma

United States
Boehringer Ingelheim

Completed

A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

China
Hat Yai Medical Education Center

Recruiting

Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study) (PARASMA)

Asthma | Airway Obstruction | Airway Remodeling | Parasympathetic Nervous System Diseases

Thailand
University Health Network, Toronto
Parkinson's Disease Foundation

Completed

Ipratropium Spray for Drooling Saliva in Parkinson's Disease

Parkinson's Disease

Canada
Boehringer Ingelheim

Completed

Actuation Indicator Trial in Patients With COPD

Pulmonary Disease, Chronic Obstructive

United States
Haukeland University Hospital

Completed

Atrovent in Exercise Induced Laryngeal Obstruction (EILO)

Exercise Induced Laryngeal Obstruction (EILO)

Norway
University of California, San Francisco

Completed

Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes (STAMINA)

Bronchospasm, Exercise-Induced

United States
London Health Sciences Centre

Unknown

Ipratropium Bromide Spray as Treatment for Sialorrhea in Children

Sialorrhea
Queen's University

Completed

Effects of Bronchodilators in Mild Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Canada
GlaxoSmithKline
University College London Hospitals

Completed

Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease

Lung Diseases, Interstitial

United Kingdom
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Boehringer Ingelheim

Completed

Ipratropium Bromide in Peri-Operative COPD

Pulmonary Disease, Chronic Obstructive

China
University of Saskatchewan
Royal University Hospital Foundation

Completed

Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Asthma

Canada
Assistance Publique - Hôpitaux de Paris

Withdrawn

Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension (BD-HTAP)

Pulmonary Arterial Hypertension
University of California, Los Angeles
Mylan Pharmaceuticals Inc; Theravance Biopharma

Recruiting

Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO)

COPD | Acute Respiratory Failure

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

Korea, Republic of
Boehringer Ingelheim

Completed

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Centre for Addiction and Mental Health

Completed

Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide

Hypersalivation

Canada
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
AstraZeneca

Completed

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (LAS-MD-35)

Chronic Obstructive Pulmonary Disease

United States, Canada
Boehringer Ingelheim

Completed

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Lithuania, Slovakia, United Kingdom
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Chronic Obstructive Pulmonary Disease

United States, Canada
Laval University
Institut universitaire de cardiologie et de pneumologie de Québec, University...

Unknown

Glittre ADL-test: Responsiveness to Acute Bronchodilation in Chronic Obstructive Pulmonary Disease (COPD) (Glittre)

Chronic Obstructive Pulmonary Disease

Canada
Laval University
McGill University; Boehringer Ingelheim

Completed

Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Canada
ThromboGenics

Terminated

Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion

Arterial Occlusive Diseases

Belgium
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
AstraZeneca

Completed

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (LAS-MD-38)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Andorra, Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, United Kingdom
Botanix Pharmaceuticals

Completed

A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis

Primary Axillary Hyperhidrosis

United States
ThromboGenics
Bacchus Vascular

Terminated

Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT (MAX-DVT)

Deep Vein Thrombosis

Ireland
AstraZeneca
Menarini Group

Completed

BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH (M-34273-46)

Pulmonary Disease, Chronic Obstructive

Italy, Spain, United Kingdom, Germany, Hungary
AstraZeneca

Completed

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada
AstraZeneca

Completed

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Argentina, Australia, Canada, Mexico, New Zealand, South Africa
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
Botanix Pharmaceuticals

Completed

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) (Cardigan II)

Axillary Hyperhidrosis

United States
AstraZeneca

Completed

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Healthy Volunteers

China
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Cothera Bioscience, Inc

Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphatic Diseases | Burkitt Lymphoma | High-grade B-cell Lymphoma | C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma | C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma | Lymphoma, High-Grade | C-Myc Gene Rearrangement

Korea, Republic of, China
Nycomed

Completed

Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)

Common Cold
Boehringer Ingelheim

Completed

Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
NPO Petrovax

Completed

Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19

Infections, Coronavirus

Belarus, Russian Federation
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
GlaxoSmithKline

Completed

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

Pulmonary Disease, Chronic Obstructive

China, Korea, Republic of
AstraZeneca

Completed

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Boehringer Ingelheim

Completed

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

3

Subscribe